Open AccessThe Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States
Author(s) -
Mark H. Eckman,
Tiffany E. Kaiser,
Kenneth E. Sherman
Publication year - 2011
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cir199
Subject(s) - medicine , hepatitis b virus , cost effectiveness , lamivudine , hepatitis b , immunology , virology , virus , risk analysis (engineering)
Hepatitis B virus (HBV) continues to cause significant morbidity and mortality in the United States. Current guidelines suggest screening populations with a prevalence of ≥2%. Our objective was to determine whether this screening threshold is cost-effective and whether screening lower-prevalence populations might also be cost-effective.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom